Free Stock Tips

Monday’s alert is exciting for several reasons.

It is a biotechnology company, and for some reason biotech stocks seem to do well in the OTC market.

Its proprietary product may treat both Parkinson’s disease and Diabetes!

Parkinson’s has combined direct and indirect cost of $25 Billion a year.

Diabetes has a combined direct and indirect cost of $218 Billion a year.

These are HUGE markets. When investors hear about this they could be very excited !!

Our alert for Monday is Amarantus Biosciences, Inc., AMBS, and the stock closed Friday at 30 cents.

Here’s some information to get you started:

AMBS is a biotechnology company engaged in the research and development of first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases.

AMBS’s most advanced product candidate is called MANF and is a therapeutic protein.

This protien offers the promise of safely and effectively protecting dopamine producing neurons from death and rejuvenating dying cells to ultimately stop the progress of Parkinson’s disease and restore normal function to patients.

AMBS received a research grant from The Michael J. Fox Foundation for Parkinson’s Research.

As many as one million Americans and up to 10 million people worldwide live with Parkinson’s disease.

AMBS’s MANF treatment is not only potentially helpful in treating Parkinsons, but Diabetes as well!

AMBS announced a joint research project with Generex Biotechnology, Inc., a Toronto-based biotechnology company developing an oral-insulin spray technology known as Oral-lyn(TM) currently in Phase III clinical trials

AMBS recently announced that the companies have selected the development of a MANF-based therapeutic for the treatment of the beta cell destruction at the root of diabetes as the second program for their joint research collaboration announced on May 31, 2011.

AMBS’s first collaboration program announced on June 8, 2011 is for the development of a MANF-based diagnostic test to identify a sub-population at risk of developing Type 1 or Type 2 diabetes.

In America, diabetes affects 25.8 million people of all ages, that’s 8.3 percent of the U.S. population!

CNN estimated in 2009 that the direct medical cost of treating diabetes will rise from $113 billion annually to $336 billion over
25 years.

Diabetes treatment is a huge market, and if AMBS’s joint research can produce an effective treatment method you can imagine how HUGE that would be.

Again, when deciding if you want to trade any stock, you must think “will other investors be excited when they learn about this company”.

Let’s recap so you can decide for yourself.

1) Bio Tech company. There are 100 examples of biotech companies that went from pennys to dollars overnight. All they need to do is come out with a press release and say they found the cure to something and it’s all over.

2) Low average daily volume. This means as new investors find out about AMBS if there are more buyers than sellers the stock should move !!

3) Great story with lots of potential in HUGE markets!!

We think as the awareness campaign rolls out and lots of people find out about this stock they will get excited about it. This excitement turns creates buying and buying makes stock prices go up.

Get yourself in a position to profit from any price gains.

AMBS belongs on your watchlist for Monday.

As always, do your own research, always use stop loss orders to protect yourself, and book your profits when in a position to do so.

Good Trading